Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma

[1]  R. Birge,et al.  Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression , 2017, Molecular Cancer Research.

[2]  Minghui Zhang,et al.  The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients , 2016, Scientific Reports.

[3]  A. Mansfield,et al.  Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non‐Small Cell Lung Cancer to Receive Immunotherapy , 2016, Clinical pharmacology and therapeutics.

[4]  J. Lunceford,et al.  Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. , 2016, The Lancet. Oncology.

[5]  Sung Sook Lee,et al.  Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity. , 2016 .

[6]  M. Shimada,et al.  Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection , 2016, Gastric Cancer.

[7]  H. Kalthoff,et al.  PD-L1 is an independent prognostic predictor in gastric cancer of Western patients , 2016, Oncotarget.

[8]  Yoon-Koo Kang,et al.  Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer. , 2016 .

[9]  Y. Jeon,et al.  Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas. , 2015, European journal of cancer.

[10]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[11]  K. Hirakawa,et al.  Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer. , 2015, Anticancer research.

[12]  Dajun Yang,et al.  Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. , 2015, International journal of clinical and experimental pathology.

[13]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[14]  D. Linehan,et al.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.

[15]  T. Aparicio,et al.  PD-1 blockade in tumors with mismatch-repair deficiency , 2015 .

[16]  Jason G. Jin,et al.  Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes , 2015, Nature Medicine.

[17]  Brian Ruffell,et al.  Macrophages and therapeutic resistance in cancer. , 2015, Cancer cell.

[18]  N. Matsumura,et al.  IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer , 2015, British Journal of Cancer.

[19]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[20]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[21]  Johann A. Gagnon-Bartsch,et al.  Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas , 2014, Gut.

[22]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[23]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[24]  J. Blay,et al.  Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.

[25]  Jing‐ying Hou,et al.  Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. , 2014, Experimental and molecular pathology.

[26]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Antonia,et al.  PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells , 2014, PloS one.

[28]  H. Baba,et al.  Identification of miR-30e* Regulation of Bmi1 Expression Mediated by Tumor-Associated Macrophages in Gastrointestinal Cancer , 2013, PloS one.

[29]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[30]  Yun Feng,et al.  Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. , 2012, Immunobiology.

[31]  R. Schwendener,et al.  Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors , 2012, BMC Cancer.

[32]  Loise M. Francisco,et al.  The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.

[33]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[34]  Yarong Wang,et al.  Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. , 2007, Cancer research.

[35]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Alberto Mantovani,et al.  Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. , 2006, European journal of cancer.

[37]  R. Herbst,et al.  Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.

[38]  Sang-Hoon Ahn,et al.  Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer , 2014, Gastric Cancer.

[39]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[40]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .